LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

LifeMD announced an exclusive co-marketing collaboration with Halozyme's subsidiary Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, an FDA-approved testosterone auto-injector. The program will launch in July 2026 across 37 states, offering patients virtual clinical evaluation, lab testing, and home delivery of medication at a transparent price of approximately $249 per month, addressing barriers to hypogonadism treatment.

06/22/2026, 8:00 AM • GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Acumen Pharmaceuticals announced it will report first quarter 2026 financial results on May 12, 2026, with a conference call and webcast at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, with topline results from the Phase 2 ALTITUDE-AD trial expected in late 2026.

05/05/2026, 4:00 PM • GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

Acumen Pharmaceuticals announced it will report Q4 and year-end 2025 financial results on March 26, 2026, with a conference call at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials.

03/19/2026, 4:00 PM • GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials following positive Phase 1 results.

03/10/2026, 4:00 PM • GlobeNewswire

Halozyme Therapeutics Projects Sustained Growth Well Into 2040

Halozyme Therapeutics raised its 2026 and multi-year financial guidance, projecting total revenue growth of 23-30% year-over-year to $1.71-$1.81 billion. Royalty revenue is expected to exceed $1 billion in 2026, growing 30-35%, one year ahead of previous projections. The company acquired Surf Bio for $300 million and forecasts adjusted EBITDA of $1.125-$1.205 billion, with non-GAAP diluted EPS of $7.75-$8.25.

01/28/2026, 1:58 PM • Benzinga

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.

12/16/2025, 1:17 PM • Benzinga

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Renaissance Group initiated a new $35.11 million position in Halozyme Therapeutics, acquiring 478,735 shares representing 1.32% of its U.S. equity assets. The biotech company offers innovative drug delivery technology and has demonstrated strong financial performance with consistent sales growth.

11/05/2025, 5:12 PM • The Motley Fool

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.

11/05/2025, 4:00 PM • GlobeNewswire

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

Pharmaceutical company argenx presented clinical trial data demonstrating VYVGART's effectiveness in treating generalized myasthenia gravis across different patient subtypes, including seronegative patients, with promising results in symptom reduction and steroid use management.

10/29/2025, 11:00 AM • GlobeNewswire

Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

A Phase 1b/2 study of subcutaneous amivantamab in recurrent or metastatic head and neck cancer demonstrated a 45% overall response rate, with rapid and durable tumor responses in patients who had previously progressed on checkpoint inhibitors and chemotherapy.

10/19/2025, 10:35 AM • GlobeNewswire

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

New data from the Phase 3 MARIPOSA study shows that amivantamab plus lazertinib significantly reduces EGFR and MET resistance mutations compared to osimertinib monotherapy in first-line advanced non-small cell lung cancer treatment.

09/06/2025, 3:10 AM • GlobeNewswire

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals will participate in two upcoming investor conferences in September 2025, presenting its ongoing research into Alzheimer's disease treatment using sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers.

08/26/2025, 4:00 PM • GlobeNewswire

Halozyme (HALO) Q2 EPS Jumps 69%

Halozyme Therapeutics reported strong Q2 2025 financial results, with non-GAAP EPS of $1.54 (69% YoY growth) and revenue of $325.7 million (41% YoY increase). The company raised full-year guidance and continues to leverage its ENHANZE drug delivery technology through pharmaceutical partnerships.

08/05/2025, 10:26 PM • The Motley Fool

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Acumen Pharmaceuticals will report Q2 2025 financial results on August 12, 2025, and host a conference call to provide a business and financial update, focusing on their Alzheimer's disease therapeutic candidate sabirnetug.

08/05/2025, 4:00 PM • GlobeNewswire